Live Yum Brands Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Apimeds Pharmaceuticals US, Inc.

Get SEC filing alerts via email and in your feed for Apimeds Pharmaceuticals US, Inc.

APUS

Apimeds Pharmaceuticals US, Inc.

About Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US develops bee venom-based therapies targeting inflammation and pain, primarily for osteoarthritis (OA) and multiple sclerosis (MS). Its core product, Apitox, is a purified bee venom formulation intended for intradermal injections. The company leverages clinical data from South Korea, aiming for FDA approval in the U.S. to offer non-opioid, potentially safer alternatives for chronic pain and inflammatory conditions.
This description was generated via AI from an annual report. Updated 10 months ago.

Latest SEC Filings from Apimeds Pharmaceuticals US, Inc.

1
1
Apimeds Pharmaceuticals US, Inc. Apimeds Pharmaceuticals Reports $35.1 Million Net Loss and Financial Challenges in Latest 10-Q

Via official filing (AI summary) | about 2 months ago | 0 comments

2
1
Apimeds Pharmaceuticals US, Inc. Apimeds Pharmaceuticals Reports Merger with MindWave Innovations and Increased Losses in Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Apimeds Pharmaceuticals US, Inc. Apimeds Pharmaceuticals Reports $1.78 Million Net Loss in Q3 2025, IPO Proceeds Boost Cash Reserves

Via official filing (AI summary) | 8 months ago | 0 comments

4
1
Apimeds Pharmaceuticals US, Inc. Apimeds Pharmaceuticals Reports $2.66 Million Net Loss in Q2 2025, IPO Boosts Cash Position

Via official filing (AI summary) | 11 months ago | 0 comments

5
1
Apimeds Pharmaceuticals US, Inc. Apimeds Pharmaceuticals Reports Increased Net Loss and IPO Completion

Via official filing (AI summary) | about 1 year ago | 0 comments